Reut Shema, PhD

As part of the aMoon investment team, Dr. Reut Shema uses her extensive scientific background and network to generate new investments and support its portfolio companies. Shema has been an essential part of aMoon’s investments in Omada Health, Stealth, Seer, PrognomIQ, MOBILion and SOPHiA Genetics. It energizes her to help translate cutting edge science into something that can help patients, while working towards bringing these innovations to market.

Previously Shema was a Principal at aMoon, and prior to that she was a VP Business Development and Scientific Advisor at Greenfield Partners, a TPG growth investment platform. She also served as an advisor to several prominent international investors and co-founded a company in the healthcare field.

Shema has more than 10 years of experience in cutting-edge research and has won numerous grants and awards for her work. She was a postdoctoral fellow at the Broad Institute of MIT and Harvard, where she led a project team to develop a novel platform for evaluating therapeutics for psychiatric diseases. Her study of ageing and neurodegenerative disease has led to the development of a novel in vivo screening method and was published in the high-impact journal PNAS.

Shema completed her PhD in Weizmann Institute of Science, where she studied long-term memory maintenance in the brain. Her work has contributed greatly to the field and is summarized in three papers, including two in the prestigious journal Science. She holds a BSc in Biology and Psychology (Magna Cum Laude) from Tel-Aviv University.